Sarcoma,Soft Tissue Clinical Trial
Official title:
Phase I Clinical Study of a Combined Modality Treatment of Sarcomas of the Extremities With Radiotherapy (RT) and Dose-escalation of Pazopanib
In this study, we aim to define the recommended dose of a VEGFR-TKI (pazopanib) in combination with RT pre-operatively given.
Study design A dose escalation trial of Pazopanib, starting at 400mg daily, orally in
combination with the standard 25 x 2Gy preoperative radiotherapy in newly diagnosed
extremity sarcoma patients. Dose of pazopanib will be escalated via 600mg to maximally
800mg. Overall treatment time of pazopanib is 40 days.
Treatment plan: Pazopanib Dose level Dose of pazopanib orally, once daily, # patients
1. (starting) 400 mg 3
2. 600 mg 3
3. (maximum) 800 mg 3
Treatment plan: radiotherapy RT is given during 5 weeks with a once daily fraction of 2 Gray
(50 Gray in 25 daily fractions)
RT planning: The dose planning should be performed by CT based Intensity Modulated RT (IMRT)
or 3 Dimensional Conformal RT (3D-RT) according to the local planning protocol of the
participating institute.
Dose specification: According to the ICRU 50/62.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04577014 -
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06114004 -
Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)
|
Phase 2 | |
| Completed |
NCT01949506 -
(SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas
|
N/A | |
| Recruiting |
NCT04595994 -
Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma
|
Phase 1 | |
| Recruiting |
NCT05235100 -
Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma
|
Phase 2 | |
| Completed |
NCT04991883 -
Analysis of the Molecular Profile of the Mixofibrosarcoma of the Extremities
|
||
| Recruiting |
NCT04122872 -
GISAR German Interdisciplinary Sarcoma Registry
|
||
| Recruiting |
NCT04910126 -
Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma
|
Phase 2 | |
| Recruiting |
NCT04219202 -
Neoadjuvant Irradiation of Retroperitoneal Soft Tissue Sarcoma With Ions Retro-Ion
|
N/A | |
| Recruiting |
NCT04028479 -
The Registry of Oncology Outcomes Associated With Testing and Treatment
|
||
| Recruiting |
NCT05886634 -
A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
|
Phase 2 | |
| Recruiting |
NCT05167994 -
Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma
|
Phase 2 | |
| Recruiting |
NCT04673942 -
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT05813327 -
Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04172805 -
Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma
|
Phase 2 | |
| Active, not recruiting |
NCT04887298 -
Study of Liposomal Annamycin for the Treatment of Subjects With Soft-Tissue Sarcomas (STS) With Pulmonary Metastases
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03600649 -
Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
|
Phase 1 | |
| Recruiting |
NCT05894018 -
Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma
|
Phase 2 | |
| Recruiting |
NCT06263231 -
A Study to Investigate Efficacy & Safety of INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
|
Phase 3 | |
| Recruiting |
NCT05614375 -
Endoscopic Surgery in the Treatment of Soft Tissue Sarcoma in Nasal and Paranasal Sinus
|